Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer
- PMID: 2189594
- DOI: 10.1007/BF00685414
Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer
Abstract
A total of 32 patients with advanced squamous-cell carcinoma of the cervix were treated with 300 mg/m2 i.v. carboplatin and 5 g/m2 ifosfamide as a 24-h i.v. infusion, both given on day 1 every 4 weeks. In all, 3 (9%) complete responses (CRs) and 19 (59%) objective responses (CR + PR) were achieved in 32 patients. Myelosuppression with leukopenia and/or thrombocytopenia of WHO grade 4 in 28% and 13% of patients, respectively, was the main toxicity. The results of our study suggest that carboplatin/ifosfamide is active as neoadjuvant treatment in advanced cervical cancer.
References
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials